Ogi Bio Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

Registered number: SC654285

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		893,281		768,436
Tangible Assets	5		64,048		53,332

			957,329		821,768
CURRENT ASSETS
Stock	6	85,794		49,124
Debtors	7	266,360		180,773
Cash at bank and in hand		55,705		92,267

		407,859		322,164
Creditors: Amounts Falling Due Within One Year	8	(325,597 )		(82,791 )

NET CURRENT ASSETS (LIABILITIES)			82,262		239,373

TOTAL ASSETS LESS CURRENT LIABILITIES			1,039,591		1,061,141

Creditors: Amounts Falling Due After More Than One Year	9		(28,822 )		(37,451 )

NET ASSETS			1,010,769		1,023,690

CAPITAL AND RESERVES
Called up share capital	10		456		385
Share premium account			2,124,157		1,497,308
Profit and Loss Account			(1,113,844 )		(474,003 )

SHAREHOLDERS' FUNDS			1,010,769		1,023,690

Page 1

Page 2

Ogi Bio Ltd

Balance Sheet (continued)

As At 31 March 2025

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Dr A F McVey

Director

15 October 2025

The notes on pages 3 to 6 form part of these financial statements.

1. General Information

Ogi Bio Ltd is a private company, limited by shares, incorporated in Scotland, registered number SC654285 . The registered office is Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

2.3. Research and Development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research is recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their expected useful economic lives, which is 3 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project the expenditure is treated as if it were all incurred in the research phase only.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold	10% Straight Line
Plant & Machinery	25% Straight Line
Fixtures & Fittings	25% Straight Line
Computer Equipment	25% Straight Line

2.5. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

Page 3

Page 4

Ogi Bio Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

2.6. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

2.7. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 12 (2024: 10)

4. Intangible Assets

	Development Costs
	£
Cost
As at 1 April 2024	900,934
Additions	438,117

As at 31 March 2025	1,339,051

Amortisation
As at 1 April 2024	132,498
Provided during the period	313,272

As at 31 March 2025	445,770

Net Book Value
As at 31 March 2025	893,281

As at 1 April 2024	768,436

Page 4

Page 5

Ogi Bio Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

5. Tangible Assets

	Land & Property
	Leasehold	Plant & Machinery	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£	£
Cost
As at 1 April 2024	14,411	47,003	8,671	9,084	79,169
Additions	-	36,045	-	-	36,045

As at 31 March 2025	14,411	83,048	8,671	9,084	115,214

Depreciation
As at 1 April 2024	2,331	16,140	3,613	3,753	25,837
Provided during the period	1,441	19,552	2,168	2,168	25,329

As at 31 March 2025	3,772	35,692	5,781	5,921	51,166

Net Book Value
As at 31 March 2025	10,639	47,356	2,890	3,163	64,048

As at 1 April 2024	12,080	30,863	5,058	5,331	53,332

6. Stock

	2025	2024
	£	£
Stock	83,148	49,124
Work in progress	2,646	-

	85,794	49,124

7. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	58,762	8,621
Other debtors	207,598	172,152

	266,360	180,773

Page 5

Page 6

Ogi Bio Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2025

8. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	170,732	60,918
Bank loans and overdrafts	5,654	6,618
Other loans	1,500	2,250
Other creditors	115,031	3,046
Taxation and social security	32,680	9,959

	325,597	82,791

9. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Bank loans	28,822	33,513
Other loans	-	3,938

	28,822	37,451

10. Share Capital

	2025	2024
	£	£
Allotted, Called up and fully paid	456	385

Page 6